With the mission to detect cancer when it is still curable, SeekInCare^® has been developed as a pan cancer detection test that takes a panoramic view of blood cell-free cancer signatures and a multi-omics approach incorporating genomic and epigenetic alterations in conjunction with clinically validated protein biomarkers. Equipped with proprietary AI- and big data-driven CRS algorithm, SeekInCare^® exhibits superior effectiveness to detect dozens of cancer types at high specificity. SeekInCare^® has been launched as a lab developed test (LDT) in China since late 2018. SeekInCare^® is intend to use for the individuals with elevated risks of cancer such as smoking, chronic hepatitis, aging, etc., in conjunction with the approved conventional single cancer type screening tests.